Jazz Pharmaceuticals (JAZZ) is back in focus after its stock broke out of a long term trading base near an all time high, despite mixed news around cancer drug Zepzelca and expectations tied to Ziihera.

Over the past year, Jazz Pharmaceuticals has seen strong momentum, with a 1 year total shareholder return of 122.45% and a 90 day share price return of 30.23%. Investors are weighing the Zepzelca trial setback against optimism around Ziihera and the recent breakout above previous highs.

If this kind of momentum has your attention, it could be a good time to see what else is moving in healthcare by browsing the 40 healthcare AI stocks.

With Jazz Pharmaceuticals trading near an all time high, investors are left asking a simple question: is the recent surge still leaving room for upside, or is the market already pricing in much of the future growth story?

Most Popular Narrative: 5.3% Undervalued

With Jazz Pharmaceuticals last closing at $243.47 against a widely followed fair value view of $257.00, the current narrative centers on whether its oncology and neuroscience engines can justify that gap.

The expected approval and launches of multiple therapies (dordaviprone for H3 K27M-mutant diffuse glioma and Zepzelca in first line maintenance for small cell lung cancer) are set to drive new revenue streams and capitalize on unmet needs in rare cancers, supporting topline growth and improved earnings consistency. Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands. This is positioning Jazz for steady long term market share and revenue growth.

Want to see what underpins that $257.00 fair value for Jazz Pharmaceuticals? The narrative leans on rapid earnings expansion, firmer margins, and a richer future earnings multiple. Curious how those moving parts fit together and what assumptions sit behind them? The full narrative lays out the numbers driving that conclusion.

Result: Fair Value of $257.00 (UNDERVALUED)

However, that story can change quickly if patent expiries in the sleep franchise hit revenues harder than expected or if key oncology launches at Jazz Pharmaceuticals stumble on uptake.

Next Steps

Given the mix of optimism around new therapies and concern about risks at Jazz Pharmaceuticals, it makes sense to move quickly and review the full breakdown of 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Jazz Pharmaceuticals?

If the Jazz Pharmaceuticals story has sharpened your focus, do not stop here. Use Simply Wall Street's tools to spot other opportunities that match your style.

• Target dependable cash flows and capital strength by screening companies through the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for potential mispriced opportunities by scanning the screener containing 18 high quality undiscovered gems that many investors may be overlooking.
• Prioritize resilience and lower volatility by filtering stocks using the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.